Sign in
Taking people in United StatesEarly phase 1

Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder

Key facts

Who runs it
University of California, San Diego
Where
San Diego, United StatesSee the site
Trial code
Status
Recruiting
Phase
Early phase 1
People taking part
200 people, planned
Started
19 Nov 2024
Expected to end
15 Aug 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Varenicline Tartrate
  • Placebo
Record updated
16 March 2026

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Persons, aged 22+
  • Ability to take oral medication and be willing to adhere to the dosing regimen
  • For participants able to become pregnant: use of highly effective contraception during study enrollment
  • Current daily tobacco use (use on 7 days per week, on average, ≥5 cigarettes per day, in the previous 3 months)
  • Tobacco use history ≥3 years
  • Endorsement of past week nicotine craving

Who cannot take part

  • Other recreational drug use in the past 30 days (besides alcohol and cannabis) verified by oral and urine fluid toxicology
  • Contraindications/conditions with special precautions for varenicline treatment (i.e., history of serious hypersensitivity or skin reactions to varenicline, history of severe renal impairment, seizures, severe cardiovascular disease, chronic or severe nausea, Stevens-Johnson syndrome, erythema multiforme, pregnancy or nursing)
  • Medical or psychiatric history affecting brain development (i.e., history and/or treatment of neurologic disorders, severe head trauma with loss of consciousness >2 minutes, or current severe Diagnostic and Statistical Manual 5th edition (DSM-5) psychiatric disorders other than tobacco use disorders)
  • Current suicidal ideation or history of suicide attempt or self-mutilatory acts in the past 12 months
  • Treatment seeking for tobacco use disorder/intent to quit within 30 days
  • Visual/vestibular problems that may make task completion difficult (i.e., motion sickness, difficulty balancing, blindness)

Where in United States

  • University California, San DiegoSan Diego, United StatesContact: Research CoordinatorTaking people

About the trial

What the trial wants to find out

The proposed project will include enrollment of 200 daily tobacco cigarette users, ages 22+, from the San Diego community. Participants will be assessed on the VR Nicotine Cue Exposure paradigm then randomized (stratified on age and sex) to receive varenicline (target dose 1mg twice daily) or placebo (n per group=100; total N=200). Following eight days of titration, participants will be assessed again on the VR Nicotine Cue Exposure paradigm. They will then be followed via mobile assessments for eight days on target dose of varenicline, and 30-days post assessment by phone, to assess short-term nicotine use behaviors.

The 2 groups in the trial

  • VareniclineTreatment being tested

    Following the baseline assessment, participants randomized to receive varenicline will complete an 8-day titration period to achieve the target dose. Titration of varenicline will be as follows: 0.5 mg once daily for Days 1-3, 0.5 mg twice daily for Days 4-7, and 1 mg twice daily on Day 8. Participants then return to the lab on Day 9 (or Days 10, 11 if necessary) for testing at the target dosage (1 mg twice daily) and continue at that dose for eight additional days (Days 10-17) for mobile monitoring.

    Treatment: Varenicline Tartrate

  • PlaceboPlacebo, for comparison

    Following the baseline assessment, participants randomized to receive placebo pill will follow the same dosing schedule as the active arm. They will return to the lab on Day 9 (or Days 10, 11 if necessary) for testing and continue at that dosing schedule for eight additional days (Days 10-17) for mobile monitoring.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 March 2026